Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update

Core Viewpoint - Gain Therapeutics, Inc. has made significant advancements in the development of its lead candidate GT-02287 for treating Parkinson's disease, showing promising results in clinical studies and financial performance improvements [2][3][5]. Pipeline Updates - The company presented initial data from the Phase 1b clinical study of GT-02287, demonstrating its disease-modifying potential for Parkinson's disease at various scientific conferences [4]. - As of March 2026, 14 out of 16 participants in the Phase 1b nine-month extension study completed 150 days of treatment, with stable MDS-UPDRS scores observed [4]. - In participants with elevated glucosylsphingosine (GluSph) levels, an average decrease of 81% was noted after 90 days of treatment with GT-02287 [4]. - The company introduced GT-04686, a novel glucocerebrosidase (GCase) allosteric modulator, which is ready for IND-enabling studies for Parkinson's disease and other neurological disorders [4]. Financial Results - Research and development (R&D) expenses decreased by $0.6 million to $10.2 million for the year ended December 31, 2025, compared to $10.8 million in 2024, primarily due to pipeline cost optimization [5]. - General and administrative (G&A) expenses decreased by $1.1 million to $8.5 million for the year ended December 31, 2025, from $9.6 million in 2024, attributed to lower stock-based compensation and legal fees [6]. - The net loss for the year ended December 31, 2025, was $20.2 million, or $0.61 per share, compared to a net loss of $20.4 million, or $0.89 per share, for the previous year [7]. Corporate Updates - Gain Therapeutics has received funding support for its lead program in Parkinson's disease from The Michael J. Fox Foundation and other organizations [14]. - The company is preparing for Phase 2 clinical development of GT-02287 in the United States, with IND clearance expected in Q2 2026 [12]. - The Phase 2 clinical trial for GT-02287 is anticipated to begin in Q3 2026, with results from the Phase 1b study expected in Q4 2026 [12].